Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Formulary restriction of selective serotonin reuptake inhibitors for depression - Potential pitfalls
Autore:
Hensley, PL; Nurnberg, HG;
Indirizzi:
Univ New Mexico, Hlth Sci Ctr, UNM Mental Hlth Ctr, Sch Med,Dept Psychiat,Albuquerque, NM 87131 USA Univ New Mexico Albuquerque NM USA 87131 ychiat,Albuquerque, NM 87131 USA
Titolo Testata:
PHARMACOECONOMICS
fascicolo: 10, volume: 19, anno: 2001,
pagine: 973 - 982
SICI:
1170-7690(2001)19:10<973:FROSSR>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRICYCLIC ANTIDEPRESSANTS; DOUBLE-BLIND; PRIMARY-CARE; COST; PAROXETINE; FLUOXETINE; IMIPRAMINE; SERTRALINE; TRIAL; DISCONTINUATION;
Tipo documento:
Editorial Material
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Nurnberg, HG Univ New Mexico, Hlth Sci Ctr, UNM Mental Hlth Ctr, Sch Med,Dept Psychiat,2600 Marble Ave NE, Albuquerque, NM 87131 USA Univ New Mexico 2600 Marble Ave NE Albuquerque NM USA 87131 A
Citazione:
P.L. Hensley e H.G. Nurnberg, "Formulary restriction of selective serotonin reuptake inhibitors for depression - Potential pitfalls", PHARMACOECO, 19(10), 2001, pp. 973-982

Abstract

The American healthcare market is currently estimated at more than $US900 billion with double digit rising costs per year. Psychotropic agent costs have more than kept pace with market increases. Medication acquisition costsare an obvious focus for limiting costs in various care systems. Restrictive formularies are a common method of attempting to limit costs. To support our opinion that a single agent is ill advised, we explored the available evidence on the intended and unintended consequences of having a single or exclusive selective serotonin reuptake inhibitor (SSRI) on a formulary. Central to this position is an assumption of the interchangeability of SSRIs; we examined the evidence for and against this through a model to determine the probability of interchangeability. We conclude that the practice of having a single SSRI on the formulary for a healthcare plan seems ill founded. Patients who switch antidepressants remain in treatment 50% longer and cost approximately 50% more to treat in a more costly treatment setting. Giving the primary care physician several antidepressant choices can provide more options to continue treatment of his or her patient in the less expensive primary care setting. In terms of cost containment, formulary restrictions are far more likely to have the opposite effect.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 06:59:09